This study explores Risk-Based Monitoring strategies and their impact on the clinical landscape. This study’s exhaustive metrics include data benchmarks and recommendations from life science industry leaders on establishing an RBM team; planning for RBM-related costs, selecting the right tools and allocating resources; and preparing for and implementing an RBM strategy. Throughout the report, data are broken down by company size and type (top 10, top 50, small pharma and medical device, contract research organizations and academia) and region in which a team operates (US, Europe and Asia). See here for more information about the New Risk-Based Monitoring Report. (Source: Cutting Edge Information, 2014).
You are here: / / New Risk-Based Monitoring System